Patents by Inventor Judy Lieberman
Judy Lieberman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220340906Abstract: The technology described herein is directed to improved chimeric molecules for, e.g, the treatment of cancer. As described herein, the inventors have developed novel chimeric aptamer-siRNA molecules (AsiCs) which demonstrate improved efficacy over existing AsiCs and which can successfully synergize in treating cancer. These AsiC's target cancer cell markers to direct therapeutic siRNA molecules specifically to cancer cells, increasing delivery efficacy and therapeutic effectiveness while reducing the potential for side effects.Type: ApplicationFiled: June 18, 2020Publication date: October 27, 2022Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy LIEBERMAN, Ying ZHANG
-
Patent number: 11384356Abstract: The invention provides aptamer-gene modulator conjugates, where the aptamer and the gene modulator are linked together. The invention further provides a method for cell-specific delivery of gene modulators to hard to transfect cells such as CD4+ cell.Type: GrantFiled: May 24, 2019Date of Patent: July 12, 2022Assignee: The Children's Medical Center CorporationInventors: Judy Lieberman, Lee Adams Wheeler
-
Patent number: 11242553Abstract: The present invention provides systems and methods for identifying, isolating, and/or characterizing microRNAs, their targets, and microRNA response elements, and for predicting their biological function.Type: GrantFiled: January 17, 2014Date of Patent: February 8, 2022Assignee: Children's Medical Center CorporationInventors: Judy Lieberman, Shen Mynn Tan
-
Patent number: 11180762Abstract: Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.Type: GrantFiled: May 10, 2019Date of Patent: November 23, 2021Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy Lieberman, Adi Gilboa-Geffen, Lee Adam Wheeler
-
Patent number: 11147828Abstract: The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. in some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells.Type: GrantFiled: December 6, 2018Date of Patent: October 19, 2021Assignee: Children's Medical Center CorporationInventors: Judy Lieberman, Erwei Song, Fengyan Yu, Xiaoqu Hu
-
Publication number: 20210267996Abstract: The present application provides chemical compounds useful, for example, in inhibiting gasdermin pore formation in a cell, inhibiting inflammasome-mediated death of a cell (pyroptosis); inhibiting cytokine secretion from a cell, inhibiting an inflammatory caspase in a cell, and/or covalently reacting with a cysteine of a gasdermin protein in a cell. These compounds are also useful in treating or preventing diseases or conditions in which inflammasome activation is implicated in pathogenesis. One example of such disease or condition is sepsis.Type: ApplicationFiled: June 27, 2019Publication date: September 2, 2021Inventors: Hao Wu, Judy Lieberman, Jun Hu, Xing Liu
-
Patent number: 10508276Abstract: The technology described herein relates to siRNAs, e.g., methods and compositions relating to the production of siRNAs in bacterial cells.Type: GrantFiled: November 6, 2017Date of Patent: December 17, 2019Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy Lieberman, Linfeng Huang
-
Publication number: 20190359987Abstract: The invention provides aptamer-gene modulator conjugates, where the aptamer and the gene modulator are linked together. The invention further provides a method for cell-specific delivery of gene modulators to hard to transfect cells such as CD4+ cell.Type: ApplicationFiled: May 24, 2019Publication date: November 28, 2019Applicant: The Children's Medical Center CorporationInventors: Judy Lieberman, Lee Adams Wheeler
-
Publication number: 20190309297Abstract: Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.Type: ApplicationFiled: May 10, 2019Publication date: October 10, 2019Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy LIEBERMAN, Adi GILBOA-GEFFEN, Lee Adam WHEELER
-
Patent number: 10435756Abstract: Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.Type: GrantFiled: May 22, 2017Date of Patent: October 8, 2019Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy Lieberman, Fabio Petrocca
-
Patent number: 10385343Abstract: Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.Type: GrantFiled: August 28, 2015Date of Patent: August 20, 2019Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy Lieberman, Adi Gilboa-Geffen, Lee Adam Wheeler
-
Patent number: 10378016Abstract: The invention provides aptamer-gene modulator conjugates, where the aptamer and the gene modulator are linked together. The invention further provides a method for cell-specific delivery of gene modulators to hard to transfect cells such as CD4+ cell.Type: GrantFiled: December 6, 2011Date of Patent: August 13, 2019Assignee: Children's Medical Center CorporationInventors: Judy Lieberman, Lee Adam Wheeler
-
Publication number: 20190224228Abstract: The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. in some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells.Type: ApplicationFiled: December 6, 2018Publication date: July 25, 2019Applicant: THE CHILDREN'S HOSPITAL CORPORATIONInventors: Judy LIEBERMAN, Erwei SONG, Fengyan YU, Xiaoqu HU
-
Publication number: 20180273950Abstract: The technology described herein relates to siRNAs, e.g., methods and compositions relating to the production of siRNAs in bacterial cells.Type: ApplicationFiled: November 6, 2017Publication date: September 27, 2018Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy LIEBERMAN, Linfeng HUANG
-
Publication number: 20180164290Abstract: Methods that enable one to specifically measure the metabolic product of a particular molecule in relatively few cells, e.g. primary cells, are described. The methods involve optionally preloading cells with labeled substrate (e.g. labeled by 13C, 15N, or 31P). The methods allow for easy identification of metabolites that are differentially generated in cells of different phenotypes. The new methods for unbiased multi-dimensional NMR screening and rapid and efficient analysis of the NMR screening identify differentially expressed metabolites in different cell or tissue types. Analysis of the differentially expressed metabolites can present unique druggable targets to which small molecule therapeutics can be designed.Type: ApplicationFiled: March 27, 2017Publication date: June 14, 2018Inventors: Elizabeth M. O'Day, Judy Lieberman, Gerhard Wagner
-
Publication number: 20180105883Abstract: Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.Type: ApplicationFiled: May 22, 2017Publication date: April 19, 2018Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy Lieberman, Fabio Petrocca
-
Patent number: 9840703Abstract: The technology described herein relates to siRNAs, e.g., methods and compositions relating to the production of siRNAs in bacterial cells.Type: GrantFiled: January 9, 2014Date of Patent: December 12, 2017Assignee: Children's Medical Center CorporationInventors: Judy Lieberman, Linfeng Huang
-
Publication number: 20170275629Abstract: Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.Type: ApplicationFiled: August 28, 2015Publication date: September 28, 2017Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Judy LIEBERMAN, Adi GILBOA-GEFFEN, Lee Adam WHEELER
-
Patent number: 9689040Abstract: Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.Type: GrantFiled: March 2, 2012Date of Patent: June 27, 2017Assignee: Children's Medical Center CorporationInventors: Judy Lieberman, Fabio Petrocca
-
Patent number: 9606106Abstract: Methods that enable one to specifically measure the metabolic product of a particular molecule in relatively few cells, e.g. primary cells, are described. The methods involve optionally preloading cells with labeled substrate (e.g. labeled by 13C, 15N, or 31P). The methods allow for easy identification of metabolites that are differentially generated in cells of different phenotypes. The new methods for unbiased multi-dimensional NMR screening and rapid and efficient analysis of the NMR screening identify differentially expressed metabolites in different cell or tissue types. Analysis of the differentially expressed metabolites can present unique druggable targets to which small molecule therapeutics can be designed.Type: GrantFiled: February 11, 2013Date of Patent: March 28, 2017Assignees: Children's Medical Center Corporation, President and Fellows of Harvard CollegeInventors: Elizabeth M. O'Day, Judy Lieberman, Gerhard Wagner